Ambit files registration statement with SEC for public offering of common stock

Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that it has filed a registration statement with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Ambit.

J.P. Morgan Securities Inc. and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Wedbush Securities, Inc. and Leerink Swann, LLC are acting as co-managers. This offering will be made only by means of a prospectus. Once available, copies of the prospectus relating to this offering may be obtained from J.P. Morgan Securities Inc. and Credit Suisse (USA) LLC.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Source:

Ambit Biosciences Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Australian company accelerating the speed of drug discovery wins prestigious Eureka prize